CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
Phase 1
Completed
- Conditions
- Cancer
- Registration Number
- NCT00374179
- Lead Sponsor
- Adnexus, A Bristol-Myers Squibb R&D Company
- Brief Summary
RATIONALE: CT-322 may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
PURPOSE: This phase I trial is studying the side effects of CT-322 in treating patients with advanced solid tumors or non-Hodgkin's lymphoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Safety and tolerability of CT-322 Throughout the study
- Secondary Outcome Measures
Name Time Method To evaluate the pharmacokinetics of CT-322 in these patients; Throughout the study to assess whether antibodies to this drug develop in these patients; and Throughout the study to make a preliminary assessment of the biological activity of CT-322 to alter tumor growth. Throughout the study
Trial Locations
- Locations (3)
Indiana University Cancer Center
🇺🇸Indianapolis, Indiana, United States
South Texas Accelerated Research Therapeutics
🇺🇸San Antonio, Texas, United States
Institute for Drug Development
🇺🇸San Antonio, Texas, United States
Indiana University Cancer Center🇺🇸Indianapolis, Indiana, United States